Novel therapy in endometrial cancer: How much will we pay? Editorial

  

Authors:	Green, A. K.; Makker, V.
Title:	Novel therapy in endometrial cancer: How much will we pay?
Keywords:	overall survival; cancer recurrence; bevacizumab; cisplatin; doxorubicin; advanced cancer; cancer combination chemotherapy; paclitaxel; endometrium carcinoma; endometrium cancer; biological marker; carboplatin; editorial; cancer therapy; cost effectiveness analysis; drug cost; mismatch repair; microsatellite instability; nicotinamide adenine dinucleotide adenosine diphosphate ribosyltransferase inhibitor; quality adjusted life year; megestrol acetate; randomized controlled trial (topic); phase 3 clinical trial (topic); lenvatinib; human; pembrolizumab; gog 209; willingness to pay
Journal Title:	Gynecologic Oncology
Volume:	162
Issue:	2
ISSN:	0090-8258
Publisher:	Elsevier Inc.
Date Published:	2021-08-01
Start Page:	243
End Page:	244
Language:	English
DOI:	10.1016/j.ygyno.2021.07.012
PUBMED:	34311843
PROVIDER:	scopus
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85111010892&doi=10.1016%2fj.ygyno.2021.07.012&partnerID=40&md5=c7756da83c5558007b220f29347c6176
Notes:	Editorial -- Export Date: 1 September 2021 -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/185972